Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
HOXA9
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "HOXA9" in MCE Product Catalog:
11
11 Publications Verification
Target:
Domaines de recherche:
EPZ004777 is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 can be used for the study of leukemia .
11
11 Publications Verification
Target:
Domaines de recherche:
EPZ004777 hydrochloride is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 hydrochloride reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 hydrochloride selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 hydrochloride can be used for the study of leukemia .
4
4 Cited Publications
Target:
Domaines de recherche:
Menin-MLL inhibitor MI-2 is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
2
2 Cited Publications
Target:
Domaines de recherche:
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .
1
1 Cited Publications
Target:
Domaines de recherche:
MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (Kd=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .
Cat. No.: HY-122623A
Pureté: 99.43%
Target:
DB818 dihydrochloride is a HOXA9 transcription factor inhibitor with an IC50 of 0.2-0.3 µM. DB818 dihydrochloride inhibits HOXA9 DNA binding and transcription, binding to AT-rich minor grooves with a Kd of 4.6 nM. DB818 dihydrochloride enters the nucleus and induces cancer cell apoptosis, cell cycle arrest, and granulocytic and monocytic differentiation, while inhibiting proliferation, colony formation, and leukemic burden. DB818 dihydrochloride downregulates MYB and BCL2, upregulates FOS, and weakly downregulates HOXA9 protein. DB818 dihydrochloride has anti-Babesia activity. DB818 dihydrochloride can be used in research related to acute myeloid leukemia, non-small cell lung cancer, and babesiosis .
Cat. No.: HY-RS06303
Target:
Domaines de recherche:
HOXA9 Human Pre-designed siRNA Set A contains three designed siRNAs for HOXA9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS17663
Target:
Domaines de recherche:
Hoxa9 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Hoxa9 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-101520A
Pureté: 98.56%
Target:
Domaines de recherche:
Dot1L-IN-1 TFA is a highly potent and selective Dot1L inhibitor with a Ki of 2 pM and an IC50 of <0.1 nM. Dot1L-IN-1 TFA potently suppresses H3K79 dimethylation (IC50=3 nM), as well as the activity of the HoxA9 promoter (IC50=17 nM) in HeLa and Molm-13 cells, respectively .
Cat. No.: HY-RS24124
Target:
Domaines de recherche:
Hoxa9 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hoxa9 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-101520
CAS No.: 2088518-50-5
Target:
Domaines de recherche:
Dot1L-IN-1 is a highly potent and selective Dot1L inhibitor with a Ki of 2 pM and an IC50 of <0.1 nM. Dot1L-IN-1 potently suppresses H3K79 dimethylation (IC50=3 nM), as well as the activity of the HoxA9 promoter (IC50=17 nM) in HeLa and Molm-13 cells, respectively .
Cat. No.: HY-155526
CAS No.: 3049681-20-8
Target:
Domaines de recherche:
FY-21 is a selective inhibitor of LSD1 (IC50=340 nM), with anti-proliferation and anti-colony formation activities. FY-21 enhances p53 expression, down-regulates HOXA9 and MEIS1 expression. FY-21 also induces leukemia cell differentiation to exhibts antitumor activity .
Cat. No.: HY-15222A
Target:
Domaines de recherche:
Menin-MLL inhibitor MI-2 dihydrochloride is a competitive and selective Menin-MLL interaction inhibitor with an IC50 value of 446 nM and a Ki value of 158 nM. Menin-MLL inhibitor MI-2 dihydrochloride downregulates the expression of target genes such as HOXA9 and MEIS1, inhibits proliferation of leukemia cells and induces apoptosis and differentiation. Menin-MLL inhibitor MI-2 dihydrochloride is proming for rasearch of MLL-rearranged acute leukemias (e.g., AML, ALL) .
Cat. No.: HY-P810365
Synonyms: HOX1G; HOXA9; Homeobox protein Hox-A9; Homeobox protein Hox-1G
Cat. No.: HY-124693
CAS No.: 869767-86-2
DB1055 is a HOXA9 inhibitor that competes with HOXA9 binding to DNA (blocking its DNA interaction activity). DB1055 induces in vitro cell growth reduction, cell apoptosis, and differentiation in human acute myeloid leukemia (AML) cells. DB1055 leads to monocyte-to-macrophage differentiation and exhibits antileukemic activities in a human THP-1 AML in vivo model. DB1055 does not impact human CD34+ bone marrow cells. DB1055 can be used for the research of acute myeloid leukemia[1].
Cat. No.: HY-100688R
CAS No.: 2029049-79-2
Domaines de recherche:
ML390 (Standard) is the analytical standard of ML390 (HY-100688). This product is intended for research and analytical applications. ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .
Cat. No.: HY-115619
Target:
Domaines de recherche:
EPZ004777 formate is an effective and selective DOT1L inhibitor, with IC50 being 0.4 nM. EPZ004777 formate reduces the levels of H3K79me2 and H3K79me1, significantly down-regulating the expression of HOXA9 and MEIS1. EPZ004777 formate selectively inhibits the proliferation of MLL rearrangement cells and promotes the differentiation and subsequent apoptosis (apoptosis) of leukemia cells. EPZ004777 formate can be used for the study of leukemia .
Cat. No.: HY-134085
CAS No.: 2351225-68-6
Target:
Domaines de recherche:
NSD-IN-1 is a benzothiazole-based covalent inhibitor of NSD1. NSD-IN-1 covalently binds the NSD1 SET domain and reduces H3K36me2 levels, thereby inhibiting the proliferation of Nup98-NSD1 leukemia cells, downregulating the expression of Meis1, Hoxa5, and Hoxa9, and inducing cell differentiation. NSD-IN-1 can be used for research on Nup98-NSD1 acute myeloid leukemia .
Cat. No.: HY-108350R
CAS No.: 1454920-20-7
Domaines de recherche:
MI-2-2 (Standard) is the analytical standard of MI-2-2 (HY-108350). This product is intended for research and analytical applications. MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (Kd=22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
